Medline (NASDAQ:MDLN) Upgraded at BNP Paribas

BNP Paribas upgraded shares of Medline (NASDAQ:MDLN) to a hold rating in a report released on Monday,Zacks.com reports.

Other research analysts have also recently issued research reports about the company. Wall Street Zen raised Medline to a “hold” rating in a research note on Saturday, January 10th. Baird R W upgraded Medline to a “strong-buy” rating in a report on Monday. Sanford C. Bernstein started coverage on Medline in a research report on Monday. They set an “outperform” rating and a $49.00 price target on the stock. Barclays assumed coverage on Medline in a report on Monday. They issued an “overweight” rating and a $50.00 price objective for the company. Finally, Wolfe Research assumed coverage on shares of Medline in a research note on Monday. They issued an “outperform” rating and a $47.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Medline has a consensus rating of “Moderate Buy” and a consensus price target of $46.70.

Medline Stock Up 1.3%

Shares of MDLN stock opened at $43.41 on Monday. Medline has a one year low of $34.89 and a one year high of $45.50.

Insider Activity

In related news, Director Charles N. Mills acquired 2,579,310 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were bought at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the transaction, the director directly owned 2,441,379 shares in the company, valued at $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of Medline stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the transaction, the insider owned 4,806,160 shares in the company, valued at $136,350,759.20. This trade represents a 55.88% decrease in their position. The disclosure for this sale is available in the SEC filing.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.